Pediatric Ulcerative Colitis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Ulcerative colitis is a chronic inflammatory bowel disease that can negatively impact the growth, nutritional well-being, and psychosocial development of affected children. Approximately 25% of individuals diagnosed with inflammatory bowel disease (IBD) are under 18. Children and adolescents with ulcerative colitis often experience a more severe disease course, more extensive intestinal involvement at diagnosis, and faster disease progression than adults. It is not uncommon for pediatric patients to present with atypical symptoms. Typical symptoms of pediatric ulcerative colitis include abdominal pain, chronic diarrhea, sometimes with blood, weight loss, fatigue, fever, and rectal bleeding. The clinical presentation of the disease is closely linked to its location and the extent of inflammation. In terms of disease extent, it is categorized into four groups: ulcerative proctitis (E1), left-sided UC (E2), extensive UC (E3), and pancolitis (E4). Disease severity is classified as either never severe (S0) or ever severe (S1). The primary approach to managing ulcerative colitis in outpatient settings involves anti-inflammatory therapy, mainly using 5-aminosalicylic acid (5-ASA) preparations like sulfasalazine and mesalamine. Acute flares of the disease in pediatric patients often respond well to corticosteroids, although their long-term use is limited due to numerous adverse effects.

·       The annual incidence of ulcerative colitis in Europe is 15.0 cases per 100,000 individuals, while in North America, it is 10.6 cases per 100,000 people.

 

Thelansis’s “Pediatric Ulcerative Colitis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pediatric Ulcerative Colitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Pediatric Ulcerative Colitis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Pediatric Ulcerative Colitis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Pediatric Ulcerative Colitis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Pediatric Ulcerative Colitis, Pediatric Ulcerative Colitis market outlook, Pediatric Ulcerative Colitis competitive landscape, Pediatric Ulcerative Colitis market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)